Healthcare provider profile · identity verified

Fahim Michel Farhat, MD

Family Practice · SUGAR LAND, TX · NPI 1902992282

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	823	253
Amlodipine Besylate	Amlodipine Besylate	479	147
Levothyroxine Sodium	Levothyroxine Sodium	355	97
Losartan Potassium	Losartan Potassium	354	103
Rosuvastatin Calcium	Rosuvastatin Calcium	265	78
Lisinopril	Lisinopril	262	80
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	245	245
Tamsulosin Hcl	Tamsulosin Hcl	240	70
Metformin Hcl	Metformin Hcl	215	67
Gabapentin	Gabapentin	190	58
Simvastatin	Simvastatin	163	44
Carvedilol	Carvedilol	153	45
Omeprazole	Omeprazole	151	45
Clopidogrel	Clopidogrel Bisulfate	148	42
Hydrochlorothiazide	Hydrochlorothiazide	147	54
Fluticasone Propionate	Fluticasone Propionate	137	53
Ezetimibe	Ezetimibe	132	39
Metoprolol Succinate	Metoprolol Succinate	129	42
Allopurinol	Allopurinol	126	37
Metformin Hcl Er	Metformin Hcl	124	34
Glipizide Er	Glipizide	112	32
Albuterol Sulfate Hfa	Albuterol Sulfate	110	39
Shingrix	Varicella-Zoster Ge/As01b/Pf	107	81
Pantoprazole Sodium	Pantoprazole Sodium	104	37
Tizanidine Hcl	Tizanidine Hcl	103	36
Eliquis	Apixaban	98	23
Ozempic	Semaglutide	82	12
Famotidine	Famotidine	79	27
Glipizide	Glipizide	77	22
Atenolol	Atenolol	76	22
Metoprolol Tartrate	Metoprolol Tartrate	76	23
Montelukast Sodium	Montelukast Sodium	76	21
Finasteride	Finasteride	72	26
Pravastatin Sodium	Pravastatin Sodium	69	23
Potassium Chloride	Potassium Chloride	68	24
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	66	66
Furosemide	Furosemide	62	22
Benazepril Hcl	Benazepril Hcl	60	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	58	15
Sertraline Hcl	Sertraline Hcl	58	23
Lorazepam	Lorazepam	57	suppressed
Glimepiride	Glimepiride	52	16
Jardiance	Empagliflozin	52	14
Azithromycin	Azithromycin	51	47
Citalopram Hbr	Citalopram Hydrobromide	47	14
Triamcinolone Acetonide	Triamcinolone Acetonide	45	20
Alprazolam	Alprazolam	41	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	41	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	12
Mirtazapine	Mirtazapine	41	17
Sildenafil Citrate	Sildenafil Citrate	39	suppressed
Tramadol Hcl	Tramadol Hcl	39	12
Farxiga	Dapagliflozin Propanediol	35	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	35	suppressed
Alendronate Sodium	Alendronate Sodium	34	15
Lovastatin	Lovastatin	34	suppressed
Clonidine Hcl	Clonidine Hcl	33	12
Warfarin Sodium	Warfarin Sodium	33	13
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	30	11
Nifedipine Er	Nifedipine	29	suppressed
Mupirocin	Mupirocin	28	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	suppressed
Januvia	Sitagliptin Phosphate	26	suppressed
Trazodone Hcl	Trazodone Hcl	26	11
Valsartan	Valsartan	26	suppressed
Spironolactone	Spironolactone	25	suppressed
Temazepam	Temazepam	25	suppressed
Prednisone	Prednisone	23	16
Baclofen	Baclofen	22	suppressed
Cefuroxime	Cefuroxime Axetil	22	17
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Hydrocortisone	Hydrocortisone	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Arnuity Ellipta	Fluticasone Furoate	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	18
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Irbesartan	Irbesartan	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	16	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	16	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Meloxicam	Meloxicam	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Synthroid	Levothyroxine Sodium	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Hyzaar	Losartan/Hydrochlorothiazide	13	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	13	suppressed
Nystatin	Nystatin	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Methylprednisolone	Methylprednisolone	12	11
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Ramipril	Ramipril	12	suppressed
Atovaquone-Proguanil Hcl	Atovaquone/Proguanil Hcl	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Constulose	Lactulose	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Folic Acid	Folic Acid	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error